Stock Price



+ 0.67

Day High:

Day Low:


4:00 PM ET on
Dec 17, 2014
Delayed ~20 min. By eSignal.


We are focused on developing and commercializing drugs that treat very serious lung infections in orphan disease populations.

Investment Thesis

Our lead product candidate, ARIKAYCE, has multiple clinical and patient benefits.

  • Proprietary inhaled liposomal formulation of the antibiotic amikacin, an FDA-approved aminoglycoside that is currently delivered intravenously
  • Engineered to deliver amikacin directly to the site of serious lung infections
  • Potential for improvements to the conventional inhalation methods of delivering drug to the pulmonary system

We have two near-term commercial opportunities in orphan lung diseases.

  • Europe: ARIKAYCE Phase 3 trial to treat CF patients with Pseudomonas lung infections enrollment completed.  Top line data reported in July, 2013.
  • US: ARIKAYCE Phase 2 trial to treat NTM enrollment well underway. Potential accelerated path to approval

We have near-term value-driving milestones.

  • Phase 3 CF-related Pseudomonas lung infection data reported in July, 2013.
  • Phase 2b NTM lung infection data expected by Q1 2014

 We have a solid and broad IP portfolio.

  • More than a decade of investment in research and development
  • Potential coverage into 2029

 We are well-capitalized and are building out our infrastructure.

  • $113.9 million in cash (as of December 31, 2013)

View all »   RSSNews Releases

Dec 15, 2014
Insmed Appoints Myrtle Potter to its Board of Directors

Dec 15, 2014
Insmed Provides End of Year Regulatory and Clinical Update

View all »Events

Dec 2, 2014
Insmed Incorporated
Webcast Listen to webcast

Nov 6, 2014
Q3 2014 Insmed Incorporated Earnings Conference Call
Webcast Listen to webcast

Investor Materials

View the latest Insmed Investor Presentation here.

Learn More

Key Clinical Publications

Insmed actively publishes and presents clinical data for ARIKAYCE.

Learn More

Email Alerts

Want to stay up to date on our news, events, and filings?

Set up your email alerts. Learn More

Investor & Media Contacts

Investor Relations
Anne Marie Fields
Senior Vice President
Phone: (212) 838-3777

Bruce Voss
Managing Director
Phone: (310) 691-7100